| Identification | Back Directory | [Name]
CCG-1423 | [CAS]
285986-88-1 | [Synonyms]
CCg
CS-1769
CCG-1423
CCG1423, >98%
CCG 1423;CCG-1423
CCG-1423 USP/EP/BP
Rho/SRF Pathway Inhibitor, CCG-1423
Rho/SRF Pathway Inhibitor, CCG-1423 - CAS 285986-88-1 - Calbiochem
N-[1-(4-chloroanilino)-1-oxopropan-2-yl]oxy-3,5-bis(trifluoromethyl)benzamide
N-(2-(4-Chloroanilino)-1-Methyl-2-oxoethoxy)-3,5-bis(trifluoroMethyl)benzaMide
N-(1-(4-chlorophenylaMino)-1-oxopropan-2-yloxy)-3,5-bis(trifluoroMethyl)benzaMide
N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)-benzamide
Benzamide, N-[2-[(4-chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)-
N-({1-[(4-Chlorophenyl)Amino]-1-Oxo-2-Propanyl}Oxy)-3,5-Bis(Trifluoromethyl)Benzamide CCG-1423 | [Molecular Formula]
C18H13ClF6N2O3 | [MDL Number]
MFCD01566719 | [MOL File]
285986-88-1.mol | [Molecular Weight]
454.751 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble5mg/mL, clear (warmed) | [form ]
White solid | [color ]
white to beige | [InChI]
1S/C18H13ClF6N2O3/c1-9(15(28)26-14-4-2-13(19)3-5-14)30-27-16(29)10-6-11(17(20,21)22)8-12(7-10)18(23,24)25/h2-9H,1H3,(H,26,28)(H,27,29) | [InChIKey]
DSMXVSGJIDFLKP-UHFFFAOYSA-N | [SMILES]
FC(F)(F)c1cc(cc(c1)C(=O)NOC(C)C(=O)Nc2ccc(cc2)Cl)C(F)(F)F |
| Hazard Information | Back Directory | [Uses]
Cell permeable inhibitor of RhoA- and RhoC-mediated signaling. Inhibits LPA-induced DNA synthesis in PC-3 prostate cancer cell lines (<1μM) and inhibits the growth of RhoC-overexpressing melanoma cell lines (A375M2 and SK-Mel-147) at nanomolar concentrations. | [Biological Activity]
CCG-1423 is a potent and specific inhibitor of Rho pathway signaling and activation of serum response factor (SRF) transcription. CCG-1423 inhibits SRF-driven luciferase expression in PC-3 cells following stimulation with constitutively active Gα13. Also CCG-1423 selectively inhibits DNA synthesisproliferation and invasion of Rho-overexpressing cell lines. | [in vivo]
CCG-1423 (0.15 mg/kg; i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice[1]. | Animal Model: | 16-week-old mice with HFD-induced obesity[1] | | Dosage: | 0.15 mg/kg | | Administration: | Intraperitoneal injection; 0.15 mg/kg once per day; for two weeks | | Result: | Improved glucose tolerance and reduced insulin levels at 30 minutes after glucose injection. |
| [storage]
+4°C |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|